Johnson & Johnson
NYSEJohnson & Johnson enters September with a fresh analyst upgrade pulling the Street's ceiling sharply higher, even as the stock trades within reach of where consensus targets clustered just a week ago. The standout event this week is a bold call from UBS. Michael Yee raised his price target to $320, up from $280, while maintaining a Buy rating — a 14% lift that lands $45 above the…
JNJ short interest drops to 0.90% of free float, down 20% over one week amid broad retreat by bearish traders.
A new long-form analysis for JNJ this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumJohnson & Johnson enters September with a fresh analyst upgrade pulling the Street's ceiling sharply higher, even as the stock trades within reach of where consensus targets clustered just a week ago. The standout…
Snapshot as of 20 Sept 2026
Johnson & Johnson has now broken above the $272.50 consensus target that was the ceiling just 48 hours ago, and the short sellers who rebuilt positions on the way up are quietly heading for the exit. The most…
Johnson & Johnson has added another $10 to its price in two days, closing Tuesday at $271.11, yet the executive selling that defined last week's note has not stopped — and the gap between where insiders are exiting and…
Johnson & Johnson has pushed further into recovery territory, adding 6.4% on the week to close at $266.73 — now sitting above several analyst price targets and approaching the upper end of the Street's consensus…
Johnson & Johnson is doing something unusual post-earnings: options traders have abandoned their defensive posture at a pace that has driven the put/call ratio to its lowest reading in a full year. The options signal…
Johnson & Johnson has printed its Q2 2026 results and the stock's reaction tells the story clearly: at $253.85, JNJ is now down 5% on the week and sitting roughly $8 below the Street's consensus mean of $262.27 — a…
Johnson & Johnson arrives at its Q2 2026 earnings release trading at $253.85, roughly $8 below the Street's consensus mean price target of $262.27 — the widest discount to analyst estimates this stock has seen in the…
Johnson & Johnson heads into Tuesday's Q2 print having given back a chunk of its recent rally, with the stock now trading below even the updated analyst consensus mean. The price reversal is the sharpest development…
Johnson & Johnson has moved further ahead of consensus this week, with the stock now trading above even the most recently upgraded analyst targets and Q2 earnings just six days away. The Street played catch-up on…
Johnson & Johnson slipped 0.8% on the week to close at $235.18, a modest pullback after the stock's strongest four-week run in over a year — and with Q2 earnings now less than four weeks away, options traders are…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for JNJ — free to start on ORTEX.
Sign up for free →Open JNJ on ORTEX